Shih IeM - Search Results

1

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Shih IeM, Kurman RJ. Shih IeM, et al. Am J Pathol. 2004 May;164(5):1511-8. doi: 10.1016/s0002-9440(10)63708-x. Am J Pathol. 2004. PMID: 15111296 Free PMC article. Review.

2

Molecular basis of gestational trophoblastic diseases.

Shih IeM, Kurman RJ. Shih IeM, et al. Curr Mol Med. 2002 Feb;2(1):1-12. doi: 10.2174/1566524023362960. Curr Mol Med. 2002. PMID: 11898845 Review.

3

Diverse tumorigenic pathways in ovarian serous carcinoma.

Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Singer G, et al. Among authors: shih iem. Am J Pathol. 2002 Apr;160(4):1223-8. doi: 10.1016/s0002-9440(10)62549-7. Am J Pathol. 2002. PMID: 11943707 Free PMC article.

4

HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis.

Singer G, Kurman RJ, McMaster MT, Shih IeM. Singer G, et al. Among authors: shih iem. Am J Surg Pathol. 2002 Jul;26(7):914-20. doi: 10.1097/00000478-200207000-00010. Am J Surg Pathol. 2002. PMID: 12131159

5

Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis.

Chang HW, Ali SZ, Cho SK, Kurman RJ, Shih IeM. Chang HW, et al. Among authors: shih iem. Clin Cancer Res. 2002 Aug;8(8):2580-5. Clin Cancer Res. 2002. PMID: 12171887

6

Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin.

Oldt RJ 3rd, Kurman RJ, Shih IeM. Oldt RJ 3rd, et al. Among authors: shih iem. Am J Pathol. 2002 Sep;161(3):1033-7. doi: 10.1016/s0002-9440(10)64264-2. Am J Pathol. 2002. PMID: 12213732 Free PMC article.

7

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM. Chang HW, et al. Among authors: shih iem. J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703. doi: 10.1093/jnci/94.22.1697. J Natl Cancer Inst. 2002. PMID: 12441325

8

Proteomic approaches to tumor marker discovery.

Rai AJ, Zhang Z, Rosenzweig J, Shih IeM, Pham T, Fung ET, Sokoll LJ, Chan DW. Rai AJ, et al. Among authors: shih iem. Arch Pathol Lab Med. 2002 Dec;126(12):1518-26. doi: 10.1043/0003-9985(2002)126<1518:PATTMD>2.0.CO;2. Arch Pathol Lab Med. 2002. PMID: 12456215

9

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

Singer G, Shih IeM, Truskinovsky A, Umudum H, Kurman RJ. Singer G, et al. Among authors: shih iem. Int J Gynecol Pathol. 2003 Jan;22(1):37-41. doi: 10.1097/00004347-200301000-00009. Int J Gynecol Pathol. 2003. PMID: 12496696

10

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IeM. Singer G, et al. Among authors: shih iem. J Natl Cancer Inst. 2003 Mar 19;95(6):484-6. doi: 10.1093/jnci/95.6.484. J Natl Cancer Inst. 2003. PMID: 12644542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results